Investment Will Be Used to Scale Product Platform, Expand Nationally, Internationally and Grow Team FREMONT, Calif., Feb. 11, 2021 /PRNewswire/ — Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. The round included […]
Other News
Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™. Breakthrough Device Designation is granted to medical devices and device-led combination products […]
Live Remote Supervision of Neuroendovascular Surgery Enabled by Olympus MedPresence®
Virtual Presence Solution Provides OR Access to Proctor Required to Oversee Critical Aneurysm Implant Procedure in New Device Trial CENTER VALLEY, Pa., Feb. 11, 2021 /PRNewswire/ — Olympus announced today its cloud-based virtual medical presence platform known as MedPresence® was critical in allowing the first use in the U.S. of a novel intracranial vascular […]
Olatec Therapeutics LLC Announces a Scientific Publication on the Positive Results in the First Known Clinical Trial with a Selective Oral NLRP3 Inhibitor, Dapansutrile, in Patients with Heart Failure
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in subjects with stable heart failure with reduced ejection fraction (HFrEF) Antonio Abbate MD PhD, the Principal Investigator, is Professor of Medicine and Medical Director of the Clinical Research Unit at […]
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ — Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C) In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-C by nearly half at 24 […]
RapidAI Acclaimed by Frost & Sullivan for Its AI-powered Modular Stroke Platform
The technology used in the Rapid® platform is highly unique and scalable and can deliver exceptional cost efficiencies to hospitals of all sizes SANTA CLARA, Calif., Feb. 10, 2021 /PRNewswire/ — Based on its recent analysis of the global intelligent imaging analysis systems market, Frost & Sullivan recognizes RapidAI with the 2020 Global Growth, Innovation & […]
First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus
Investigational device has the potential to transform a half-century-old standard of care BOSTON, Feb. 10, 2021 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating […]
CardiacSense Medical Grade Watch receives CE Mark for continuous detection of Atrial Fibrillation
– The watch will begin shipping in EU as a medical device for continuous measurement of heart rate and arrhythmias at ECG-level accuracy CAESAREA, Israel, Feb. 10, 2021 /PRNewswire/ — CardiacSense – a digital health company that developed and clinically verified a medical grade watch capable of detecting and remotely monitoring Atrial Fibrillation (A-Fib) and Heart […]
New Study Published in JACC Clinical EP Validates that Cardiologs’ AI Eliminates Nearly Two-Thirds of False Positives in Remote Monitoring for Atrial Fibrillation
PARIS and BOSTON, Feb. 10, 2021 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced that results of a clinical study the company conducted in collaboration with Valley Health System have been published in the Journal of the American College of Cardiology Clinical Electrophysiology (“JACC Clinical EP”). The findings show […]
First Patient Enrolled in SELUTION SLR™ SUCCESS PTA Study
NYON, Switzerland, Feb. 10, 2021 /PRNewswire/ — MedAlliance has announced enrolment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon SELUTION SLR™ for the treatment of patients with peripheral artery disease (PAD). SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, […]



